1. Home
  2. ALX vs ANIP Comparison

ALX vs ANIP Comparison

Compare ALX & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alexander's Inc.

ALX

Alexander's Inc.

HOLD

Current Price

$264.00

Market Cap

1.3B

Sector

Real Estate

ML Signal

HOLD

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$81.34

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALX
ANIP
Founded
1928
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.9B
IPO Year
1994
1999

Fundamental Metrics

Financial Performance
Metric
ALX
ANIP
Price
$264.00
$81.34
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$110.00
AVG Volume (30 Days)
25.5K
268.1K
Earning Date
05-04-2026
05-08-2026
Dividend Yield
7.20%
N/A
EPS Growth
N/A
419.23
EPS
0.91
1.28
Revenue
$213,183,000.00
$206,547,000.00
Revenue This Year
N/A
$21.01
Revenue Next Year
N/A
$17.59
P/E Ratio
$287.05
$63.79
Revenue Growth
N/A
2.47
52 Week Low
$201.28
$62.14
52 Week High
$271.02
$99.50

Technical Indicators

Market Signals
Indicator
ALX
ANIP
Relative Strength Index (RSI) 67.62 55.16
Support Level $227.27 $76.73
Resistance Level N/A $83.61
Average True Range (ATR) 5.84 2.27
MACD 2.25 0.24
Stochastic Oscillator 83.72 77.99

Price Performance

Historical Comparison
ALX
ANIP

About ALX Alexander's Inc.

Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Share on Social Networks: